JP2005531520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531520A5 JP2005531520A5 JP2003579734A JP2003579734A JP2005531520A5 JP 2005531520 A5 JP2005531520 A5 JP 2005531520A5 JP 2003579734 A JP2003579734 A JP 2003579734A JP 2003579734 A JP2003579734 A JP 2003579734A JP 2005531520 A5 JP2005531520 A5 JP 2005531520A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- dichlorophenyl
- alkyl
- pyridine
- nicotinonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 117
- 125000001424 substituent group Chemical group 0.000 claims 64
- 125000003118 aryl group Chemical group 0.000 claims 53
- 229910052739 hydrogen Inorganic materials 0.000 claims 53
- 239000001257 hydrogen Substances 0.000 claims 53
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 45
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 43
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 150000002367 halogens Chemical class 0.000 claims 34
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 34
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- -1 cyclopropylmethoxy Chemical group 0.000 claims 20
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 6
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 208000030814 Eating disease Diseases 0.000 claims 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 235000014632 disordered eating Nutrition 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 125000006606 n-butoxy group Chemical group 0.000 claims 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 4
- 230000037406 food intake Effects 0.000 claims 4
- 235000012631 food intake Nutrition 0.000 claims 4
- HQPPJTUGTUANCS-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)pyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)N)=CC=1C1=CC=C(Cl)C=C1 HQPPJTUGTUANCS-UHFFFAOYSA-N 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- UHNJRKVMGGJKDS-UHFFFAOYSA-N 2-(3-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1=CC=CC(Cl)=C1 UHNJRKVMGGJKDS-UHFFFAOYSA-N 0.000 claims 2
- OMLGPXXIQYFOSM-UHFFFAOYSA-N 2-(4-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1OC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N OMLGPXXIQYFOSM-UHFFFAOYSA-N 0.000 claims 2
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 2
- VXENZXMHWSMSBB-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-[(3,4-difluorophenyl)methoxy]pyridine Chemical compound C1=C(F)C(F)=CC=C1COC(N=C1C=2C(=CC(Cl)=CC=2)Cl)=CC=C1C1=CC=C(Cl)C=C1 VXENZXMHWSMSBB-UHFFFAOYSA-N 0.000 claims 2
- RXTUAOJEIAWETB-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-(3,5-dichlorophenoxy)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1=CC(Cl)=CC(Cl)=C1 RXTUAOJEIAWETB-UHFFFAOYSA-N 0.000 claims 2
- TUQXVTIUEVMLEA-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-(5-chloropyridin-3-yl)oxy-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1=CN=CC(Cl)=C1 TUQXVTIUEVMLEA-UHFFFAOYSA-N 0.000 claims 2
- MJPHWVJHMTWHPX-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[(3-chlorophenyl)methoxy]-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=CC(Cl)=C1 MJPHWVJHMTWHPX-UHFFFAOYSA-N 0.000 claims 2
- PVSSDPWBXZUKBJ-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-cyclohexyloxy-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1CCCCC1 PVSSDPWBXZUKBJ-UHFFFAOYSA-N 0.000 claims 2
- DTUGSOQLNBOHAQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-n-ethylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)NCC)=CC=1C1=CC=C(Cl)C=C1 DTUGSOQLNBOHAQ-UHFFFAOYSA-N 0.000 claims 2
- RJWQSFKRHOUSJO-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-n-methylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)NC)=CC=1C1=CC=C(Cl)C=C1 RJWQSFKRHOUSJO-UHFFFAOYSA-N 0.000 claims 2
- RWZVVBVAUPBWHG-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-n-propan-2-ylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)NC(C)C)=CC=1C1=CC=C(Cl)C=C1 RWZVVBVAUPBWHG-UHFFFAOYSA-N 0.000 claims 2
- SPDRNWALGCLXAG-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-n-pyrrolidin-1-ylpyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1OC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C(=O)NN1CCCC1 SPDRNWALGCLXAG-UHFFFAOYSA-N 0.000 claims 2
- OMIHQKYKCRPXPH-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1OC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N OMIHQKYKCRPXPH-UHFFFAOYSA-N 0.000 claims 2
- ANBYXDYPKJILHK-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3-fluorophenoxy)pyridine-3-carbonitrile Chemical compound FC1=CC=CC(OC=2C(=CC(=C(C=3C(=CC(Cl)=CC=3)Cl)N=2)C=2C=CC(Cl)=CC=2)C#N)=C1 ANBYXDYPKJILHK-UHFFFAOYSA-N 0.000 claims 2
- GVMVKUDTCSWOCV-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-fluorophenoxy)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1OC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N GVMVKUDTCSWOCV-UHFFFAOYSA-N 0.000 claims 2
- QIERXXZDSLXNAV-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-methoxyphenoxy)pyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1OC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N QIERXXZDSLXNAV-UHFFFAOYSA-N 0.000 claims 2
- PUPIRIVKMRMBDY-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(2,4-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N PUPIRIVKMRMBDY-UHFFFAOYSA-N 0.000 claims 2
- FPBZDYQUXHBXBO-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-n-methylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)NC)=CC=1C1=CC=C(Cl)C=C1 FPBZDYQUXHBXBO-UHFFFAOYSA-N 0.000 claims 2
- XQQYSNIMBGWIEC-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N XQQYSNIMBGWIEC-UHFFFAOYSA-N 0.000 claims 2
- LJRDDUPQALIJGH-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methyl]pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N LJRDDUPQALIJGH-UHFFFAOYSA-N 0.000 claims 2
- NJTKTPGFVGYUCD-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,5-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC(COC=2C(=CC(=C(C=3C(=CC(Cl)=CC=3)Cl)N=2)C=2C=CC(Cl)=CC=2)C#N)=C1 NJTKTPGFVGYUCD-UHFFFAOYSA-N 0.000 claims 2
- ZZUKFXGVUSGZCV-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(4-fluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N ZZUKFXGVUSGZCV-UHFFFAOYSA-N 0.000 claims 2
- GTFYXEYTWAYYLT-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[1-(4-fluorophenyl)ethoxy]pyridine-3-carbonitrile Chemical compound C=1C=C(F)C=CC=1C(C)OC(C(=CC=1C=2C=CC(Cl)=CC=2)C#N)=NC=1C1=CC=C(Cl)C=C1Cl GTFYXEYTWAYYLT-UHFFFAOYSA-N 0.000 claims 2
- MQPIPCZNBMMMNO-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-phenylmethoxy-n-piperidin-1-ylpyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C(=O)NN2CCCCC2)=C1OCC1=CC=CC=C1 MQPIPCZNBMMMNO-UHFFFAOYSA-N 0.000 claims 2
- QUAZWCZRNVNLQQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-phenylmethoxypyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=CC=C1 QUAZWCZRNVNLQQ-UHFFFAOYSA-N 0.000 claims 2
- ONJZNBNUXSLKBK-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-pyridin-3-yloxypyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1=CC=CN=C1 ONJZNBNUXSLKBK-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N Methyl nicotinate Natural products COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- AWZPBECDKVFELS-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-2-(5-chloropyridin-3-yl)oxy-6-(2,4-dichlorophenyl)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(Cl)C=NC=2)C(C(=O)OC)=CC=1C1=CC=C(Cl)C=C1 AWZPBECDKVFELS-UHFFFAOYSA-N 0.000 claims 2
- CYDGBODJXMLPGY-UHFFFAOYSA-N methyl 6-(4-chlorophenyl)-2-methoxy-5-phenylpyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C=1N=C(OC)C(C(=O)OC)=CC=1C1=CC=CC=C1 CYDGBODJXMLPGY-UHFFFAOYSA-N 0.000 claims 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- 229960001238 methylnicotinate Drugs 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- GTHBLKNJWUFWAO-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxyethyl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NCCOC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N GTHBLKNJWUFWAO-UHFFFAOYSA-N 0.000 claims 2
- KTRFZZLLQIRRJI-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxyethyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)C1=CC=CC=C1 KTRFZZLLQIRRJI-UHFFFAOYSA-N 0.000 claims 2
- AYYXHEXYNSQCSS-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxyethyl]cyclobutanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)C1CCC1 AYYXHEXYNSQCSS-UHFFFAOYSA-N 0.000 claims 2
- WEXCSKKFHLUZDO-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxyethyl]cyclopentanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)C1CCCC1 WEXCSKKFHLUZDO-UHFFFAOYSA-N 0.000 claims 2
- AIBYWAIPRHPVNS-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxyethyl]cyclopropanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)C1CC1 AIBYWAIPRHPVNS-UHFFFAOYSA-N 0.000 claims 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 claims 1
- YAGBSNMZQKEFCO-SNVBAGLBSA-N (2r)-n-ethyl-1-phenylpropan-2-amine Chemical compound CCN[C@H](C)CC1=CC=CC=C1 YAGBSNMZQKEFCO-SNVBAGLBSA-N 0.000 claims 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 1
- QTZPRMCKSZATQD-DEOSSOPVSA-N (3s)-3-(2-carboxyethylsulfanyl)-3-[2-(8-phenyloctyl)phenyl]propanoic acid Chemical compound OC(=O)CCS[C@@H](CC(O)=O)C1=CC=CC=C1CCCCCCCCC1=CC=CC=C1 QTZPRMCKSZATQD-DEOSSOPVSA-N 0.000 claims 1
- YPJYSMZDZCLFSP-UHFFFAOYSA-N (4-chlorophenyl) pyridine-3-carboxylate Chemical compound C1=CC(Cl)=CC=C1OC(=O)C1=CC=CN=C1 YPJYSMZDZCLFSP-UHFFFAOYSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 claims 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- YUWKBDWJAFHYKS-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylmethoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=C(OCO2)C2=C1 YUWKBDWJAFHYKS-UHFFFAOYSA-N 0.000 claims 1
- USLYPTAGZMJSFX-UHFFFAOYSA-N 2-(2-aminoethoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCCN)=NC=1C1=CC=C(Cl)C=C1Cl USLYPTAGZMJSFX-UHFFFAOYSA-N 0.000 claims 1
- LKXZBMVRDVCZJE-UHFFFAOYSA-N 2-(2-aminoethoxy)-6-(2-chlorophenyl)-5-(4-chlorophenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCCN)=NC=1C1=CC=CC=C1Cl LKXZBMVRDVCZJE-UHFFFAOYSA-N 0.000 claims 1
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 claims 1
- WQJAQDPNEGQJOV-UHFFFAOYSA-N 2-(benzotriazol-1-yl)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(N2C3=CC=CC=C3N=N2)N=C1C1=CC=C(Cl)C=C1Cl WQJAQDPNEGQJOV-UHFFFAOYSA-N 0.000 claims 1
- QZDZEKUNVSHKNV-UHFFFAOYSA-N 2-(cyclohexylamino)-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1NC1CCCCC1 QZDZEKUNVSHKNV-UHFFFAOYSA-N 0.000 claims 1
- DSMXPBHIZBTIKH-UHFFFAOYSA-N 2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1CCCCC1 DSMXPBHIZBTIKH-UHFFFAOYSA-N 0.000 claims 1
- KAGGTBVIUAZYDS-UHFFFAOYSA-N 2-[(3-chlorophenyl)methoxy]-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=CC(Cl)=C1 KAGGTBVIUAZYDS-UHFFFAOYSA-N 0.000 claims 1
- RDFUNVZSUJZOJY-UHFFFAOYSA-N 2-[(4-chlorophenyl)methoxy]-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=C(Cl)C=C1 RDFUNVZSUJZOJY-UHFFFAOYSA-N 0.000 claims 1
- MVVHKDSTRHNAAK-UHFFFAOYSA-N 2-[(6-chloropyridin-3-yl)methoxy]-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=C(Cl)N=C1 MVVHKDSTRHNAAK-UHFFFAOYSA-N 0.000 claims 1
- NNWDXJFZYJCWJY-UHFFFAOYSA-N 2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-methylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C(=O)NC)C(OCCCC)=NC=1C1=CC=C(Cl)C=C1Cl NNWDXJFZYJCWJY-UHFFFAOYSA-N 0.000 claims 1
- FQXFBMUSAUCRII-UHFFFAOYSA-N 2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-propylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C(=O)NCCC)C(OCCCC)=NC=1C1=CC=C(Cl)C=C1Cl FQXFBMUSAUCRII-UHFFFAOYSA-N 0.000 claims 1
- NETQVEVBNHBPTM-UHFFFAOYSA-N 2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C(N)=O)C(OCCCC)=NC=1C1=CC=C(Cl)C=C1Cl NETQVEVBNHBPTM-UHFFFAOYSA-N 0.000 claims 1
- JXGPDXZQCGOKKH-UHFFFAOYSA-N 2-butoxy-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(C)C=CC=1C=1C=C(C#N)C(OCCCC)=NC=1C1=CC=C(Cl)C=C1Cl JXGPDXZQCGOKKH-UHFFFAOYSA-N 0.000 claims 1
- IAMWQMDLEVUITJ-UHFFFAOYSA-N 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-hexylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(Cl)C(C(=O)NCCCCCC)=CC=1C1=CC=C(Cl)C=C1 IAMWQMDLEVUITJ-UHFFFAOYSA-N 0.000 claims 1
- RPFZUITZBLTUOO-UHFFFAOYSA-N 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-piperidin-1-ylpyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC(C(=O)NN2CCCCC2)=C(Cl)N=C1C1=CC=C(Cl)C=C1Cl RPFZUITZBLTUOO-UHFFFAOYSA-N 0.000 claims 1
- WCYFXIAPEXIKJF-UHFFFAOYSA-N 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-propylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(Cl)C(C(=O)NCCC)=CC=1C1=CC=C(Cl)C=C1 WCYFXIAPEXIKJF-UHFFFAOYSA-N 0.000 claims 1
- JIWIQRVNRXHQFB-UHFFFAOYSA-N 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(Cl)N=C1C1=CC=C(Cl)C=C1Cl JIWIQRVNRXHQFB-UHFFFAOYSA-N 0.000 claims 1
- WWEBTCYXHWIIOG-UHFFFAOYSA-N 2-chloro-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C1=CC(C#N)=C(Cl)N=C1C1=CC=C(Cl)C=C1Cl WWEBTCYXHWIIOG-UHFFFAOYSA-N 0.000 claims 1
- OIZLIIZGPGGNNC-UHFFFAOYSA-N 2-chloro-6-(2-chlorophenyl)-5-(4-chlorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(Cl)N=C1C1=CC=CC=C1Cl OIZLIIZGPGGNNC-UHFFFAOYSA-N 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- LMLYCGPFHNKUPY-UHFFFAOYSA-N 3-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]-1,1-dimethylurea Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCCNC(=O)N(C)C)=NC=1C1=CC=CC=C1Cl LMLYCGPFHNKUPY-UHFFFAOYSA-N 0.000 claims 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 1
- CHQOEWXKGJCWIT-UHFFFAOYSA-N 4-[[3-cyano-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridin-2-yl]oxymethyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(C)=CC=2)C=C1C#N CHQOEWXKGJCWIT-UHFFFAOYSA-N 0.000 claims 1
- LVSOLKQESYDRAH-UHFFFAOYSA-N 4-[[3-cyano-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridin-2-yl]oxymethyl]benzoic acid Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=C(C(O)=O)C=C1 LVSOLKQESYDRAH-UHFFFAOYSA-N 0.000 claims 1
- LBXOZCWTESHVCI-UHFFFAOYSA-N 5,6-bis(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C(=CC(Cl)=CC=2)Cl)C=C1C#N LBXOZCWTESHVCI-UHFFFAOYSA-N 0.000 claims 1
- ZRPASWQEENKWNT-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-n-methylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC2CCCCC2)C(C(=O)NC)=CC=1C1=CC=C(Cl)C=C1 ZRPASWQEENKWNT-UHFFFAOYSA-N 0.000 claims 1
- HXIISXBVANMJQB-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-n-propylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC2CCCCC2)C(C(=O)NCCC)=CC=1C1=CC=C(Cl)C=C1 HXIISXBVANMJQB-UHFFFAOYSA-N 0.000 claims 1
- QORYPHZOTDZZRS-UHFFFAOYSA-N 5-(4-chlorophenyl)-3-cyano-n-cyclohexyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl QORYPHZOTDZZRS-UHFFFAOYSA-N 0.000 claims 1
- ZLNSIXLRTVPHOQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-3-cyano-n-cyclopentyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(C(=O)NC2CCCC2)N=C1C1=CC=C(Cl)C=C1Cl ZLNSIXLRTVPHOQ-UHFFFAOYSA-N 0.000 claims 1
- OQZHLMHPPFOOFP-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(2-methoxyethoxy)pyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCCOC)=NC=1C1=CC=C(Cl)C=C1Cl OQZHLMHPPFOOFP-UHFFFAOYSA-N 0.000 claims 1
- CDLZBFGSDGAHBB-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(2-methylimidazol-1-yl)pyridine-3-carbonitrile Chemical compound CC1=NC=CN1C1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N CDLZBFGSDGAHBB-UHFFFAOYSA-N 0.000 claims 1
- HOMBUOQYQSXUJK-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(2-oxopyridin-1-yl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(N2C(C=CC=C2)=O)N=C1C1=CC=C(Cl)C=C1Cl HOMBUOQYQSXUJK-UHFFFAOYSA-N 0.000 claims 1
- GJYAHGCCGZMMCK-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-n',n'-dimethylpyridine-3-carbohydrazide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)NN(C)C)=CC=1C1=CC=C(Cl)C=C1 GJYAHGCCGZMMCK-UHFFFAOYSA-N 0.000 claims 1
- KLRIKMQKTSWQHL-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-n,n'-dimethylpyridine-3-carbohydrazide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)N(C)NC)=CC=1C1=CC=C(Cl)C=C1 KLRIKMQKTSWQHL-UHFFFAOYSA-N 0.000 claims 1
- FIAZIHVNURJPLM-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)pyridine-3-carboxylic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)O)=CC=1C1=CC=C(Cl)C=C1 FIAZIHVNURJPLM-UHFFFAOYSA-N 0.000 claims 1
- RROSEAQEXROOAE-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4,4-dimethyl-2-oxo-1,3-oxazolidin-3-yl)pyridine-3-carbonitrile Chemical compound CC1(C)COC(=O)N1C1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N RROSEAQEXROOAE-UHFFFAOYSA-N 0.000 claims 1
- ZODUEYNVTIAXJD-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-fluorophenyl)sulfanylpyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1SC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N ZODUEYNVTIAXJD-UHFFFAOYSA-N 0.000 claims 1
- IMRWUPISBZVMEE-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(oxan-2-ylmethoxy)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1OCCCC1 IMRWUPISBZVMEE-UHFFFAOYSA-N 0.000 claims 1
- FGRUXAONANJQNR-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(oxolan-3-ylmethoxy)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1COCC1 FGRUXAONANJQNR-UHFFFAOYSA-N 0.000 claims 1
- WWFVJABFOVSPCE-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(oxolan-3-yloxy)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1COCC1 WWFVJABFOVSPCE-UHFFFAOYSA-N 0.000 claims 1
- QYAVZZBAEXNVQJ-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(propan-2-ylamino)pyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(NC(C)C)=NC=1C1=CC=C(Cl)C=C1Cl QYAVZZBAEXNVQJ-UHFFFAOYSA-N 0.000 claims 1
- IIVWKLCTLFBGMU-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(triazol-1-yl)pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(N2N=NC=C2)N=C1C1=CC=C(Cl)C=C1Cl IIVWKLCTLFBGMU-UHFFFAOYSA-N 0.000 claims 1
- KGTLMCVOORCATH-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-n',n'-dimethylpyridine-3-carbohydrazide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)NN(C)C)=CC=1C1=CC=C(Cl)C=C1 KGTLMCVOORCATH-UHFFFAOYSA-N 0.000 claims 1
- OGDLQAXDJMXJMB-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-n-ethylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)NCC)=CC=1C1=CC=C(Cl)C=C1 OGDLQAXDJMXJMB-UHFFFAOYSA-N 0.000 claims 1
- LMEABUVWBQNILW-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-n-propan-2-ylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)NC(C)C)=CC=1C1=CC=C(Cl)C=C1 LMEABUVWBQNILW-UHFFFAOYSA-N 0.000 claims 1
- XWQCEKPUKCEUCO-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-n-propylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)NCCC)=CC=1C1=CC=C(Cl)C=C1 XWQCEKPUKCEUCO-UHFFFAOYSA-N 0.000 claims 1
- BSNHBQOBCSOTBM-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carboxylic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)O)=CC=1C1=CC=C(Cl)C=C1 BSNHBQOBCSOTBM-UHFFFAOYSA-N 0.000 claims 1
- CYSXCAPJJBQVJK-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[2-(1,3-dioxoisoindol-2-yl)ethoxy]pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCCN1C(=O)C2=CC=CC=C2C1=O CYSXCAPJJBQVJK-UHFFFAOYSA-N 0.000 claims 1
- MOKPPJCLOFMZMS-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[[4-(trifluoromethyl)phenyl]methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N MOKPPJCLOFMZMS-UHFFFAOYSA-N 0.000 claims 1
- ZHZJBQASMLCQAN-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-ethoxypyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCC)=NC=1C1=CC=C(Cl)C=C1Cl ZHZJBQASMLCQAN-UHFFFAOYSA-N 0.000 claims 1
- QJDJPGDIOUXVEC-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-imidazol-1-ylpyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(N2C=NC=C2)N=C1C1=CC=C(Cl)C=C1Cl QJDJPGDIOUXVEC-UHFFFAOYSA-N 0.000 claims 1
- MHQZSJOVNZQMTO-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-phenylmethoxy-n-propylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)NCCC)=CC=1C1=CC=C(Cl)C=C1 MHQZSJOVNZQMTO-UHFFFAOYSA-N 0.000 claims 1
- IHBTYWJEHJBZKM-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-piperidin-1-yloxypyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1ON1CCCCC1 IHBTYWJEHJBZKM-UHFFFAOYSA-N 0.000 claims 1
- AAZPJOPTMNOCRC-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-propan-2-yloxypyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OC(C)C)=NC=1C1=CC=C(Cl)C=C1Cl AAZPJOPTMNOCRC-UHFFFAOYSA-N 0.000 claims 1
- JKFMYHSBYJKYIY-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-pyridin-2-yloxypyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1=CC=CC=N1 JKFMYHSBYJKYIY-UHFFFAOYSA-N 0.000 claims 1
- FBWFBRDKBXZJGC-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n,n-dimethyl-2-phenylmethoxypyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)N(C)C)=CC=1C1=CC=C(Cl)C=C1 FBWFBRDKBXZJGC-UHFFFAOYSA-N 0.000 claims 1
- APOBSGRZASPDHP-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-ethyl-2-phenylmethoxypyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)NCC)=CC=1C1=CC=C(Cl)C=C1 APOBSGRZASPDHP-UHFFFAOYSA-N 0.000 claims 1
- ANQSRDBEIISAMR-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-hexylpyridine-2-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C1=NC(C(=O)NCCCCCC)=CC=C1C1=CC=C(Cl)C=C1 ANQSRDBEIISAMR-UHFFFAOYSA-N 0.000 claims 1
- HSDHYQYLBBAZAZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-hexylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C1=CC(C(=O)NCCCCCC)=CN=C1C1=CC=C(Cl)C=C1Cl HSDHYQYLBBAZAZ-UHFFFAOYSA-N 0.000 claims 1
- WGPQQSBYSCRPJE-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-methyl-2-phenylmethoxypyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)NC)=CC=1C1=CC=C(Cl)C=C1 WGPQQSBYSCRPJE-UHFFFAOYSA-N 0.000 claims 1
- HWCBKPRGTKEEBQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-pentyl-2-phenylmethoxypyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)NCCCCC)=CC=1C1=CC=C(Cl)C=C1 HWCBKPRGTKEEBQ-UHFFFAOYSA-N 0.000 claims 1
- LELUVKLGICFGRZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-n-piperidin-1-ylpyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl LELUVKLGICFGRZ-UHFFFAOYSA-N 0.000 claims 1
- MSQOMIZPPUECAT-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-cycloheptyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)NC2CCCCCC2)N=C1C1=CC=C(Cl)C=C1Cl MSQOMIZPPUECAT-UHFFFAOYSA-N 0.000 claims 1
- FCWFVBTUXIMCLC-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-cyclohexyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl FCWFVBTUXIMCLC-UHFFFAOYSA-N 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- DNCDSDKQWQPNCH-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OC1=CC=C(F)C(F)=C1 DNCDSDKQWQPNCH-UHFFFAOYSA-N 0.000 claims 1
- XZRXKMWOKOSQAQ-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-5-(4-fluorophenyl)-n-methylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)NC)=CC=1C1=CC=C(F)C=C1 XZRXKMWOKOSQAQ-UHFFFAOYSA-N 0.000 claims 1
- SGNSBIINTHBCRE-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-5-(4-fluorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=C(F)C(F)=C1 SGNSBIINTHBCRE-UHFFFAOYSA-N 0.000 claims 1
- RTBJNGFNAAXBIP-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-5-(4-fluorophenyl)pyridine-3-carboxylic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)O)=CC=1C1=CC=C(F)C=C1 RTBJNGFNAAXBIP-UHFFFAOYSA-N 0.000 claims 1
- TZAHVDWCFRJFHI-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=C(F)C(F)=C1 TZAHVDWCFRJFHI-UHFFFAOYSA-N 0.000 claims 1
- JFODXTDJABNDTF-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methylamino]-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1NCC1=CC=C(F)C(F)=C1 JFODXTDJABNDTF-UHFFFAOYSA-N 0.000 claims 1
- BGHKQLWJOSXJKW-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[1-(4-fluorophenyl)ethoxy]-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(F)C=CC=1C(C)OC(C(=CC=1C=2C=CC(C)=CC=2)C#N)=NC=1C1=CC=C(Cl)C=C1Cl BGHKQLWJOSXJKW-UHFFFAOYSA-N 0.000 claims 1
- ZNJHMCCESTVYNA-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[2-(diethylamino)ethoxy]-5-(4-methylphenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(C)C=CC=1C=1C=C(C#N)C(OCCN(CC)CC)=NC=1C1=CC=C(Cl)C=C1Cl ZNJHMCCESTVYNA-UHFFFAOYSA-N 0.000 claims 1
- WIPHSAYHCAMZBR-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-5-(3,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1COC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=C(Cl)C(Cl)=CC=2)C=C1C#N WIPHSAYHCAMZBR-UHFFFAOYSA-N 0.000 claims 1
- AADPLDNXZYIJGL-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-2-(pyridin-3-ylmethoxy)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1OCC1=CC=CN=C1 AADPLDNXZYIJGL-UHFFFAOYSA-N 0.000 claims 1
- XCBTXDCTHGSSSU-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-(4-methylpiperazin-1-yl)pyridine-3-carbonitrile Chemical compound C1CN(C)CCN1C1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(C)=CC=2)C=C1C#N XCBTXDCTHGSSSU-UHFFFAOYSA-N 0.000 claims 1
- WZHNBOAUHCIGBS-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-piperidin-1-ylpyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C1=CC(C#N)=C(N2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl WZHNBOAUHCIGBS-UHFFFAOYSA-N 0.000 claims 1
- WIHSZYDVQNEUME-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-pyrrolidin-1-ylpyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C1=CC(C#N)=C(N2CCCC2)N=C1C1=CC=C(Cl)C=C1Cl WIHSZYDVQNEUME-UHFFFAOYSA-N 0.000 claims 1
- MLXAGNPFIQLVNQ-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-(3,4-difluorophenoxy)pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1OC1=NC(C=2C(=CC=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N MLXAGNPFIQLVNQ-UHFFFAOYSA-N 0.000 claims 1
- ICHXOGAWNBSFFW-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-(5-chloropyridin-3-yl)oxypyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC=CC=2)Cl)=CC(C#N)=C1OC1=CN=CC(Cl)=C1 ICHXOGAWNBSFFW-UHFFFAOYSA-N 0.000 claims 1
- QIWZQPFRVZCLQR-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1COC1=NC(C=2C(=CC=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N QIWZQPFRVZCLQR-UHFFFAOYSA-N 0.000 claims 1
- JXNMKWAHBYRQHC-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carboxamide Chemical compound C=1C=CC=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)N)=CC=1C1=CC=C(Cl)C=C1 JXNMKWAHBYRQHC-UHFFFAOYSA-N 0.000 claims 1
- RPKOORYOQWEMOY-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[2-(1,3-dioxoisoindol-2-yl)ethoxy]pyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC=CC=2)Cl)=CC(C#N)=C1OCCN1C(=O)C2=CC=CC=C2C1=O RPKOORYOQWEMOY-UHFFFAOYSA-N 0.000 claims 1
- BHDIOAOUAHFWJS-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-methoxy-5-phenyl-n-piperidin-1-ylpyridine-3-carboxamide Chemical compound C=1C=CC=CC=1C=1C=C(C(=O)NN2CCCCC2)C(OC)=NC=1C1=CC=C(Cl)C=C1 BHDIOAOUAHFWJS-UHFFFAOYSA-N 0.000 claims 1
- CXJDKKJRPIMZLL-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-methoxy-5-phenylpyridine-3-carbonitrile Chemical compound C=1C=CC=CC=1C=1C=C(C#N)C(OC)=NC=1C1=CC=C(Cl)C=C1 CXJDKKJRPIMZLL-UHFFFAOYSA-N 0.000 claims 1
- ALQIYEHKHMRAOK-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-phenyl-2-phenylmethoxypyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=NC(OCC=2C=CC=CC=2)=C(C#N)C=C1C1=CC=CC=C1 ALQIYEHKHMRAOK-UHFFFAOYSA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- IXJCHVMUTFCRBH-SDUHDBOFSA-N 7-[(1r,2s,3e,5z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCC\C=C/C=C/[C@@H]([C@H](O)C=1C=C(C=CC=1)C(F)(F)F)SC1=CC=C2C(=O)C=C(C(O)=O)OC2=C1 IXJCHVMUTFCRBH-SDUHDBOFSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 1
- 102000006835 Lamins Human genes 0.000 claims 1
- 108010047294 Lamins Proteins 0.000 claims 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 1
- HUFUSBCFKOXKGM-UHFFFAOYSA-N [5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)pyridin-3-yl]methanol Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(CO)=CC=1C1=CC=C(Cl)C=C1 HUFUSBCFKOXKGM-UHFFFAOYSA-N 0.000 claims 1
- AXJIRPDFXDOHRG-UHFFFAOYSA-N [5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-phenylmethoxypyridin-3-yl]-piperidin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C(=O)N2CCCCC2)=C1OCC1=CC=CC=C1 AXJIRPDFXDOHRG-UHFFFAOYSA-N 0.000 claims 1
- MVBCVQCUGBLHOZ-UHFFFAOYSA-N [5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridin-3-yl]-piperidin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1C1=CC(C(=O)N2CCCCC2)=CN=C1C1=CC=C(Cl)C=C1Cl MVBCVQCUGBLHOZ-UHFFFAOYSA-N 0.000 claims 1
- SOXMSMNHKFAJTR-UHFFFAOYSA-N [6-(4-chlorophenyl)-2-methoxy-5-phenylpyridin-3-yl]-piperidin-1-ylmethanone Chemical compound C=1C=CC=CC=1C=1C=C(C(=O)N2CCCCC2)C(OC)=NC=1C1=CC=C(Cl)C=C1 SOXMSMNHKFAJTR-UHFFFAOYSA-N 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 229960003790 alimemazine Drugs 0.000 claims 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 229960002469 antazoline Drugs 0.000 claims 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims 1
- 229960002837 benzphetamine Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 1
- 229960003291 chlorphenamine Drugs 0.000 claims 1
- 229950007046 chlorphentermine Drugs 0.000 claims 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960002881 clemastine Drugs 0.000 claims 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 1
- HXCXASJHZQXCKK-UHFFFAOYSA-N clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 claims 1
- 229950000649 clortermine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229960001140 cyproheptadine Drugs 0.000 claims 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 229960001271 desloratadine Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960000632 dexamfetamine Drugs 0.000 claims 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 claims 1
- 229960001882 dexchlorpheniramine Drugs 0.000 claims 1
- 229960004597 dexfenfluramine Drugs 0.000 claims 1
- 229960004890 diethylpropion Drugs 0.000 claims 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 229960001003 etilamfetamine Drugs 0.000 claims 1
- 229960001582 fenfluramine Drugs 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- IQUFSXIQAFPIMR-UHFFFAOYSA-N fenproporex Chemical compound N#CCCNC(C)CC1=CC=CC=C1 IQUFSXIQAFPIMR-UHFFFAOYSA-N 0.000 claims 1
- 229960005231 fenproporex Drugs 0.000 claims 1
- 229960003592 fexofenadine Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- DLGIIZAHQPTVCJ-UHFFFAOYSA-N furfenorex Chemical compound C=1C=COC=1CN(C)C(C)CC1=CC=CC=C1 DLGIIZAHQPTVCJ-UHFFFAOYSA-N 0.000 claims 1
- 229950005457 furfenorex Drugs 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229960000930 hydroxyzine Drugs 0.000 claims 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 229960001361 ipratropium bromide Drugs 0.000 claims 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 1
- 229950000831 iralukast Drugs 0.000 claims 1
- 229960001268 isoetarine Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 1
- 229960000511 lactulose Drugs 0.000 claims 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 1
- 210000005053 lamin Anatomy 0.000 claims 1
- 239000008141 laxative Substances 0.000 claims 1
- 230000002475 laxative effect Effects 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229950005223 levamfetamine Drugs 0.000 claims 1
- 229960000299 mazindol Drugs 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- YVSPILKMRVHOIO-UHFFFAOYSA-N methyl 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(Cl)C(C(=O)OC)=CC=1C1=CC=C(Cl)C=C1 YVSPILKMRVHOIO-UHFFFAOYSA-N 0.000 claims 1
- ITHLUZVSRDGUDH-UHFFFAOYSA-N methyl 2-chloro-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(Cl)C(C(=O)OC)=CC=1C1=CC=C(F)C=C1 ITHLUZVSRDGUDH-UHFFFAOYSA-N 0.000 claims 1
- QMJYOLOCGQHJKZ-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)OC)=CC=1C1=CC=C(Cl)C=C1 QMJYOLOCGQHJKZ-UHFFFAOYSA-N 0.000 claims 1
- YUWBNZDQMZVVJU-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)OC)=CC=1C1=CC=C(Cl)C=C1 YUWBNZDQMZVVJU-UHFFFAOYSA-N 0.000 claims 1
- UTWXABYUOACVIT-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-phenylmethoxypyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)OC)=CC=1C1=CC=C(Cl)C=C1 UTWXABYUOACVIT-UHFFFAOYSA-N 0.000 claims 1
- KVXDVYLPPQXAHE-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-2-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C1=NC(C(=O)OC)=CC=C1C1=CC=C(Cl)C=C1 KVXDVYLPPQXAHE-UHFFFAOYSA-N 0.000 claims 1
- ONMFQDDAOPVNAT-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C1=CC(C(=O)OC)=CN=C1C1=CC=C(Cl)C=C1Cl ONMFQDDAOPVNAT-UHFFFAOYSA-N 0.000 claims 1
- SFDDICSKQCCWNI-UHFFFAOYSA-N methyl 6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-5-(4-fluorophenyl)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OC=2C=C(F)C(F)=CC=2)C(C(=O)OC)=CC=1C1=CC=C(F)C=C1 SFDDICSKQCCWNI-UHFFFAOYSA-N 0.000 claims 1
- HQPHHBZYWYBDSV-UHFFFAOYSA-N methyl 6-(2,4-dichlorophenyl)-2-[(3,4-difluorophenyl)methoxy]-5-(4-fluorophenyl)pyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C(OCC=2C=C(F)C(F)=CC=2)C(C(=O)OC)=CC=1C1=CC=C(F)C=C1 HQPHHBZYWYBDSV-UHFFFAOYSA-N 0.000 claims 1
- GDUWQCHLDMAQIJ-UHFFFAOYSA-N methyl 6-(4-chlorophenyl)-5-phenyl-2-phenylmethoxypyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C=1N=C(OCC=2C=CC=CC=2)C(C(=O)OC)=CC=1C1=CC=CC=C1 GDUWQCHLDMAQIJ-UHFFFAOYSA-N 0.000 claims 1
- KTVRMIKUWRAHRV-UHFFFAOYSA-N methyl 6-(4-chlorophenyl)-5-phenyl-2-prop-2-enoxypyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C=1N=C(OCC=C)C(C(=O)OC)=CC=1C1=CC=CC=C1 KTVRMIKUWRAHRV-UHFFFAOYSA-N 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005127 montelukast Drugs 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- ZNMWFDKCPWCBBU-UHFFFAOYSA-N n-(2,4-dichlorophenyl)pyridine-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1NC(=O)C1=CC=CC=N1 ZNMWFDKCPWCBBU-UHFFFAOYSA-N 0.000 claims 1
- DCHLFHWAVVOYAE-UHFFFAOYSA-N n-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCCNC(=O)C)=NC=1C1=CC=CC=C1Cl DCHLFHWAVVOYAE-UHFFFAOYSA-N 0.000 claims 1
- CIXDKYUPPPRLEN-UHFFFAOYSA-N n-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)C1=CC=CC=C1 CIXDKYUPPPRLEN-UHFFFAOYSA-N 0.000 claims 1
- NDBYLZDOQHFWAW-UHFFFAOYSA-N n-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]benzenesulfonamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC=CC=2)Cl)=CC(C#N)=C1OCCNS(=O)(=O)C1=CC=CC=C1 NDBYLZDOQHFWAW-UHFFFAOYSA-N 0.000 claims 1
- QXAHQDXOJJGMTF-UHFFFAOYSA-N n-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]cyclopropanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)C1CC1 QXAHQDXOJJGMTF-UHFFFAOYSA-N 0.000 claims 1
- SZELKDSSDKPXMW-UHFFFAOYSA-N n-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]methanesulfonamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(OCCNS(=O)(=O)C)=NC=1C1=CC=CC=C1Cl SZELKDSSDKPXMW-UHFFFAOYSA-N 0.000 claims 1
- WGSTXIWZGKLQHP-UHFFFAOYSA-N n-[2-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxyethyl]morpholine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC=CC=2)Cl)=CC(C#N)=C1OCCNC(=O)N1CCOCC1 WGSTXIWZGKLQHP-UHFFFAOYSA-N 0.000 claims 1
- KSJQOSXAKMGPBK-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(C#N)C(NC(=O)C(C)(C)C)=NC=1C1=CC=C(Cl)C=C1Cl KSJQOSXAKMGPBK-UHFFFAOYSA-N 0.000 claims 1
- SVXRSXKESZVKBA-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]-3,4-difluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)NC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(Cl)=CC=2)C=C1C#N SVXRSXKESZVKBA-UHFFFAOYSA-N 0.000 claims 1
- SDAUNWZYMCZJPR-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=CC(C#N)=C1NC(=O)C1=CC=CC=C1 SDAUNWZYMCZJPR-UHFFFAOYSA-N 0.000 claims 1
- JOKMVCAQHVPHHU-UHFFFAOYSA-N n-benzoyl-n-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC(C#N)=C(N(C(=O)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1Cl JOKMVCAQHVPHHU-UHFFFAOYSA-N 0.000 claims 1
- MLZSFBBPARUGFA-UHFFFAOYSA-N n-benzyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)NCC=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1Cl MLZSFBBPARUGFA-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 229960002657 orciprenaline Drugs 0.000 claims 1
- 239000002357 osmotic agent Substances 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 229960000436 phendimetrazine Drugs 0.000 claims 1
- 229960001190 pheniramine Drugs 0.000 claims 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 claims 1
- 229960003209 phenmetrazine Drugs 0.000 claims 1
- 229960003562 phentermine Drugs 0.000 claims 1
- 229960000395 phenylpropanolamine Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229960004583 pranlukast Drugs 0.000 claims 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960003910 promethazine Drugs 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 229960003223 tripelennamine Drugs 0.000 claims 1
- 229960001128 triprolidine Drugs 0.000 claims 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims 1
- 229960004764 zafirlukast Drugs 0.000 claims 1
- 0 *c(cc1)ccc1-c(nc(*)c(*)c1*)c1C1=CC=C(*)C=S=C1 Chemical compound *c(cc1)ccc1-c(nc(*)c(*)c1*)c1C1=CC=C(*)C=S=C1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36833402P | 2002-03-28 | 2002-03-28 | |
| US60/368,334 | 2002-03-28 | ||
| PCT/US2003/009005 WO2003082191A2 (en) | 2002-03-28 | 2003-03-24 | Substituted 2,3-diphenyl pyridines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531520A JP2005531520A (ja) | 2005-10-20 |
| JP2005531520A5 true JP2005531520A5 (https=) | 2006-05-18 |
Family
ID=28675472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003579734A Pending JP2005531520A (ja) | 2002-03-28 | 2003-03-24 | 置換２，３−ジフェニルピリジン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7271266B2 (https=) |
| EP (1) | EP1492784A4 (https=) |
| JP (1) | JP2005531520A (https=) |
| AU (1) | AU2003225964B2 (https=) |
| CA (1) | CA2479744A1 (https=) |
| WO (1) | WO2003082191A2 (https=) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1575901B1 (en) * | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| JPWO2005040135A1 (ja) * | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| FR2866340B1 (fr) * | 2004-02-13 | 2006-11-24 | Sanofi Synthelabo | Derives d'oxazole, leur preparation et leur utilisation en therapeutique. |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| FR2876691B1 (fr) * | 2004-10-18 | 2006-12-29 | Sanofi Aventis Sa | Derives de pyridine, leur preparation, leur application en therapeutique |
| PT1868999E (pt) * | 2005-04-06 | 2009-08-06 | Hoffmann La Roche | Derivados de piridino-3-carboxamida como agonistas inversos de cb1 |
| CA2606288A1 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| FR2899899A1 (fr) * | 2006-04-14 | 2007-10-19 | Sanofi Aventis Sa | Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique |
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| US7728014B2 (en) * | 2006-09-07 | 2010-06-01 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity |
| DE102006043520A1 (de) * | 2006-09-12 | 2008-03-27 | Bayer Healthcare Ag | 2-Phenoxynikotinsäure-Derivate und ihre Verwendung |
| US7781593B2 (en) * | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| US20100048632A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine GPCR Agonists |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| DE102007042754A1 (de) * | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
| PL2203439T3 (pl) | 2007-09-14 | 2011-06-30 | Addex Pharmaceuticals Sa | 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony |
| US8445435B2 (en) * | 2007-09-28 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Mast cell stabilizers in the treatment of obesity |
| FR2922209B1 (fr) * | 2007-10-12 | 2010-06-11 | Sanofi Aventis | 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| PL2240018T3 (pl) * | 2008-01-04 | 2017-01-31 | Schabar Res Ass Llc | Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy |
| US8349876B2 (en) | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| US8158654B2 (en) | 2008-05-19 | 2012-04-17 | The University Of Tennessee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| WO2009151098A1 (ja) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| US20100099696A1 (en) * | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| EP3372591B1 (en) | 2009-02-09 | 2021-05-26 | Georgetown University | Cadherin-11 inhibitors and methods of use thereof |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153912A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| TWI488852B (zh) | 2009-12-11 | 2015-06-21 | Shionogi & Co | 衍生物 |
| EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| KR20140057652A (ko) * | 2011-09-12 | 2014-05-13 | 에프. 호프만-라 로슈 아게 | Hdl-콜레스테롤 상승제로서의 3-피리딘 카복실산 하이드라자이드 |
| KR20150072412A (ko) | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 억제제 |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| KR101493882B1 (ko) * | 2013-02-28 | 2015-02-17 | 서울대학교산학협력단 | 신규한 헤테로아릴카르복스아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2014224784B2 (en) | 2013-03-07 | 2018-03-08 | F. Hoffmann-La Roche Ag | Novel pyrazol derivatives |
| CN105121436B (zh) * | 2013-03-26 | 2018-07-27 | 豪夫迈·罗氏有限公司 | 新的吡啶衍生物 |
| WO2014177527A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
| AU2014261585B2 (en) | 2013-05-02 | 2018-03-08 | F. Hoffmann-La Roche Ag | Purine derivatives as CB2 receptor agonists |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| KR20220049612A (ko) | 2014-01-21 | 2022-04-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| HUE053734T2 (hu) | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
| JP6869891B2 (ja) * | 2015-10-09 | 2021-05-12 | 三井化学アグロ株式会社 | ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤 |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| PT4293009T (pt) | 2015-12-22 | 2025-09-08 | Zogenix International Ltd | Composições de fenfluramina e métodos de preparação das mesmas |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| AU2017315273B2 (en) | 2016-08-24 | 2021-04-29 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| WO2018190349A1 (ja) * | 2017-04-10 | 2018-10-18 | 三井化学アグロ株式会社 | ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤 |
| US11234970B2 (en) | 2017-04-10 | 2022-02-01 | Mitsui Chemicals Agro, Inc. | Parasitic pest control agents comprising pyridone compounds as active ingredients and methods for using the same |
| JP2020121925A (ja) * | 2017-04-10 | 2020-08-13 | 三井化学アグロ株式会社 | ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物 |
| WO2018190323A1 (ja) * | 2017-04-10 | 2018-10-18 | 三井化学アグロ株式会社 | ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法 |
| WO2018190325A1 (ja) * | 2017-04-10 | 2018-10-18 | 三井化学アグロ株式会社 | ピリドン化合物を有効成分として含有する木材保存剤およびその使用方法 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| CN110194735B (zh) * | 2018-02-27 | 2022-02-22 | 河南大学 | 一种手性3-(2-吡啶)-3-芳基取代胺类化合物的可见光不对称催化合成方法 |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| US20210401776A1 (en) * | 2018-11-30 | 2021-12-30 | Zogenix International Limited | Method of treating refractory epilepsy syndromes using fenfluramine enantiomers |
| US12514846B2 (en) | 2020-07-15 | 2026-01-06 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach |
| CA3124579C (en) | 2020-07-15 | 2026-03-31 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| EP4181912A1 (en) | 2020-07-15 | 2023-05-24 | Schabar Research Associates LLC | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| EP4467537A4 (en) * | 2022-01-25 | 2025-04-30 | Chengdu Easton Biopharmaceuticals Co., Ltd. | PYRIDINE DERIVATIVE, MANUFACTURING METHOD THEREOF AND USE THEREOF |
| CN117582438B (zh) * | 2023-07-24 | 2026-03-17 | 成都硕德药业有限公司 | 吡啶类衍生物的药物组合物、制备方法及用途 |
| US12043609B1 (en) | 2023-10-13 | 2024-07-23 | King Faisal University | 6′(4-methoxyphenyl)-2′-alkoxy-3,4′-bipyridine-3′-carbonitrile as antimicrobial compounds |
| CN118641677B (zh) * | 2024-08-16 | 2024-11-05 | 北京京丰制药集团有限公司 | 尼可刹米原料中杂质的检测方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2139779B1 (de) | 1971-08-09 | 1972-12-07 | Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt | Verfahren zur Herstellung von chlorsubstituierten Benzyl und Benzal Chloriden |
| FR2198737B1 (https=) * | 1972-09-13 | 1975-11-28 | Serdex | |
| FR2248027B2 (https=) | 1973-10-18 | 1977-09-09 | Serdex | |
| DE2416295C3 (de) | 1974-04-04 | 1980-01-10 | Studiengesellschaft Kohle Mbh, 4330 Muelheim | Verfahren zur Herstellung von ein- oder mehrfach substituierten Pyridinen durch katalytische Mischcyclisierung von Alkinen mit Nitrilen in Gegenwart einer Kobalt-Komplexverbindung |
| DE2712694A1 (de) | 1977-03-23 | 1978-09-28 | Degussa | Verfahren zur herstellung substituierter pyridine |
| US4533666A (en) | 1983-06-22 | 1985-08-06 | Eli Lilly And Company | 6-Phenyl-2,3-bis-(4-methoxyphenyl)-pyridine derivatives having anti-inflammatory activity |
| EP0308020A3 (en) * | 1987-09-18 | 1990-12-05 | Merck & Co. Inc. | 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof |
| CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
| DE3835028A1 (de) | 1988-10-14 | 1990-04-19 | Basf Ag | Oximether-derivate, verfahren zu ihrer herstellung und diese enthaltende fungizide |
| US5077142A (en) | 1989-04-20 | 1991-12-31 | Ricoh Company, Ltd. | Electroluminescent devices |
| NZ237097A (en) | 1990-02-26 | 1993-12-23 | Squibb & Sons Inc | Pyridine derivatives substituted in the 3-position by a phosphinic moiety. |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| WO1992002513A1 (en) | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| US5217982A (en) | 1990-09-25 | 1993-06-08 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive properties |
| US5380700A (en) | 1991-03-26 | 1995-01-10 | Kumiai Chemical Industries Co., Ltd. | Pyridine derivatives, herbicidal composition containing the same, and method for killing weeds |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JP3188286B2 (ja) | 1991-08-20 | 2001-07-16 | 塩野義製薬株式会社 | フェニルメトキシイミノ化合物およびそれを用いる農業用殺菌剤 |
| JPH0616638A (ja) | 1992-03-30 | 1994-01-25 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物およびその医薬用途 |
| JPH05331164A (ja) | 1992-05-26 | 1993-12-14 | Meiji Seika Kaisha Ltd | アンジオテンシンｉｉ拮抗性イソインドール誘導体 |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5292734A (en) | 1993-04-23 | 1994-03-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| JPH07247214A (ja) | 1994-03-09 | 1995-09-26 | Yoshitomi Pharmaceut Ind Ltd | β−アミロイド生成および／または沈着の抑制剤 |
| US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| US5686470A (en) | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| WO1997004778A1 (en) | 1995-07-27 | 1997-02-13 | Eli Lilly And Company | Pyridine compounds, intermediates, processes, compositions, and methods |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| EP0887340A4 (en) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US5672609A (en) | 1996-07-18 | 1997-09-30 | Eli Lilly And Company | Pyridine compounds, intermediates compositions and methods of use |
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| IL127441A (en) | 1996-07-18 | 2003-02-12 | Merck Frosst Canada Inc | Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors |
| DE69822449T2 (de) | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| TR199902012T2 (xx) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| GB2323841A (en) | 1997-04-04 | 1998-10-07 | Ferring Bv Group Holdings | Pyridine derivatives with anti-tumor and anti-inflammatory activity |
| KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
| GB9810920D0 (en) | 1998-05-21 | 1998-07-22 | Merck Sharp & Dohme | Therapeutic use |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| BR9916536A (pt) | 1998-12-23 | 2002-01-02 | Searle & Co | Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| JP4180723B2 (ja) | 1999-03-12 | 2008-11-12 | 高橋 保 | アザメタラシクロペンタジエン類とアルキン類との反応によるピリジン類の製造方法 |
| JP4603646B2 (ja) * | 1999-11-15 | 2010-12-22 | 富士フイルムファインケミカルズ株式会社 | 新規なジピリジル誘導体 |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| JP4388189B2 (ja) | 2000-03-08 | 2009-12-24 | 独立行政法人科学技術振興機構 | ピリジン誘導体及びその製造方法 |
| FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| WO2002055502A1 (en) * | 2001-01-02 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine derivatives useful as cyclooxygenase inhibitor |
| US6538017B2 (en) | 2001-03-09 | 2003-03-25 | Ortho-Mcneil Pharmaceutical, Inc. | Aminopyrrolidine sulfonamides as serine protease inhibitors |
| US20030153801A1 (en) * | 2001-05-29 | 2003-08-14 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| FR2837706A1 (fr) | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
| US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| GB0222495D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| GB0222493D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| GB0314261D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
-
2003
- 2003-03-24 WO PCT/US2003/009005 patent/WO2003082191A2/en not_active Ceased
- 2003-03-24 US US10/508,043 patent/US7271266B2/en not_active Expired - Fee Related
- 2003-03-24 AU AU2003225964A patent/AU2003225964B2/en not_active Ceased
- 2003-03-24 CA CA002479744A patent/CA2479744A1/en not_active Abandoned
- 2003-03-24 JP JP2003579734A patent/JP2005531520A/ja active Pending
- 2003-03-24 EP EP03745578A patent/EP1492784A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531520A5 (https=) | ||
| JP5509104B2 (ja) | １１β−ＨＳＤ１モジュレータとしてのアザビシクロ［３．２．１］オクチル誘導体 | |
| US7196080B2 (en) | Phenylpyridinecarbonylpiperazinederivative | |
| US7271266B2 (en) | Substituted 2,3-diphenyl pyridines | |
| KR100785580B1 (ko) | 질환 치료용 술폰아미드 유도체 | |
| JP6023846B2 (ja) | ホスホジエステラーゼ阻害剤としての１−フェニル−２−ピリジニルアルキルアルコールの誘導体 | |
| US6949573B2 (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| CA2712017C (en) | Compounds having crth2 antagonist activity | |
| US7767715B2 (en) | Sulfonamide derivatives for the treatment of diseases | |
| TWI491603B (zh) | 甲吡啶醯胺（ｐｉｃｏｌｉｎａｍｉｄｅ）與嘧啶－４－甲醯胺化合物、其製造方法及含其之醫藥組合物 | |
| JP4216196B2 (ja) | Ｎｐｙアンタゴニストとしてのキノリン誘導体 | |
| JP2009503107A5 (https=) | ||
| JP2004504301A5 (https=) | ||
| CN102459158B (zh) | 新的酰胺和脒衍生物和其用途 | |
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2005509024A5 (https=) | ||
| JP3966897B2 (ja) | ベータ２アゴニストとしての（２−ヒドロキシ−２−（４−ヒドロキシ−３−ヒドロキシメチルフェニル）−エチルアミノ）−プロピル−フェニル誘導体 | |
| ZA200210207B (en) | N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives. | |
| KR20050088194A (ko) | 치환된 아미드 | |
| TW200824687A (en) | Compounds that inhibit TRPV1 and uses thereof | |
| TWI299040B (en) | Pyrimidine derivatives | |
| US8507493B2 (en) | Amide and amidine derivatives and uses thereof | |
| NL1028599C2 (nl) | Verbindingen voor de behandeling van ziekten. | |
| JP2007529499A (ja) | β２受容体アゴニストとしてのフェニルアミノエタノール誘導体 | |
| CA2669311A1 (en) | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |